Hundreds of CRISPR patents have been granted around the world, and the number of applications continues to grow at a rapid pace.

The US patent office declares an interference between the intellectual property held by the Broad Institute and several patent applications filed by the University of California—opposite its previous ruling.

The higher court’s decision to uphold the ruling of the Patent Trial and Appeal Board essentially ends the intellectual property battle in the US.

In an ongoing legal battle, the University of California, Berkeley has challenged the Broad Institute’s patent claims on the gene editing technology.

This is the second patent the European Patent Office has issued to the institutions of Jennifer Doudna, Emmanuelle Charpentier, and colleagues.

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

The University of California files a brief in its appeal challenging the ruling that the Broad Institute’s group would retain its CRISPR genome-editing patent.

The Broad Institute and others sign on to participate in a platform designed to streamline the licensing process. 

The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.